Mark E. Kaufmann
Algemeen Directeur bij The Linguist Institute, Inc.
Oorsprong van het eerstegraads netwerk van Mark E. Kaufmann
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 20 | |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases.
10
| Extinct | Medical Distributors | 10 |
The Linguist Institute, Inc.
 The Linguist Institute, Inc. Internet Software/ServicesTechnology Services The Linguist Institute, Inc. operates web and mobile language learning platform. It provides e-learning services. The company was founded by Mark E. Kaufmann and Steven M. Kaufman in 2007 and is headquartered in West Vancouver, Canada.
1
| Holding Company | Internet Software/Services | 1 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Mark E. Kaufmann via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
Immunex Corp.
 Immunex Corp. BiotechnologyHealth Technology Immunex Corporation is a leading biopharmaceutical company dedicated to improving lives through immune system science innovation | Biotechnology | General Counsel Founder | |
| JOHNSON & JOHNSON | Pharmaceuticals: Major | Corporate Officer/Principal Sales & Marketing | |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Biotechnology | General Counsel General Counsel Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
BBN Corp.
 BBN Corp. Information Technology ServicesTechnology Services Part of Verizon Communications, Inc., BBN Corp. is a company that offers summer programs for pre-k through 12th grade in Cambridge, MA. Campers can explore all camps by age, date, and interest and register online. The company is known for its special and theme days offered throughout camp, including Wow Wednesdays, Theme Thursdays, and events on Fun Fridays. Last year, 98% of camp families said they would recommend summer camp at BB&N to their friends. BBN was acquired by GTE Corp. on August 15, 1997 for $615.45 million. | Information Technology Services | Corporate Officer/Principal | |
| SAREPTA THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
Viventia Biotech, Inc.
 Viventia Biotech, Inc. BiotechnologyHealth Technology Viventia Biotech, Inc. discovers, develops, manufactures, and commercializes monoclonal antibody products. Its products are used to treat head, neck, and bladder cancers. The company was founded by Albert D. Friesen in 1995 and is headquartered in Toronto, Canada | Biotechnology | Director/Board Member | |
| THERATECHNOLOGIES INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Biothera, Inc.
 Biothera, Inc. Miscellaneous Commercial ServicesCommercial Services Biothera, Inc. develops natural gluco polysaccharide that engages and directs natural innate immune systems. The company was founded by Daniel Conners in 1997 and is headquartered in Eagan, MN. | Miscellaneous Commercial Services | Director/Board Member | |
| ANTHERA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Chairman | |
U.S. Renal Care, Inc.
 U.S. Renal Care, Inc. Medical/Nursing ServicesHealth Services U.S. Renal Care, Inc. engages in the provision of in-center and at-home hemodialysis and peritoneal dialysis services for end stage renal disease. The company was founded by Walter E. Schwing Jr., Robert L. Schwing, Jack N. Harrington, and John Christopher Brengard in 2000 and is headquartered in Plano, TX. | Medical/Nursing Services | Chief Tech/Sci/R&D Officer | |
| REATA PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| ONCOSEC MEDICAL INCORPORATED | Medical/Nursing Services | Director/Board Member | |
Vium, Inc.
 Vium, Inc. Information Technology ServicesTechnology Services Vium, Inc. provides technology for preclinical drug discovery services. It offers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline. The company was founded by Timothy L. Robertson and Jonathan Betts-Lacroix in 2013 and is headquartered in San Mateo, CA. | Information Technology Services | Chairman | |
| University of Pennsylvania | College/University | Masters Business Admin | |
| SILENCE THERAPEUTICS PLC | Miscellaneous Commercial Services | Chief Executive Officer | |
Affymax Research Institute
 Affymax Research Institute Miscellaneous Commercial ServicesCommercial Services Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Executive Officer | |
| McGill University | College/University | Corporate Officer/Principal Graduate Degree | |
| Brooklyn College | College/University | Undergraduate Degree | |
| Syracuse University | College/University | Doctorate Degree | |
| University of Toronto | College/University | Masters Business Admin Graduate Degree | |
| University of California, Berkeley | College/University | Corporate Officer/Principal Corporate Officer/Principal Undergraduate Degree | |
| University of Colorado Health Sciences Center | College/University | Corporate Officer/Principal | |
| University of Montréal | College/University | Corporate Officer/Principal Doctorate Degree | |
| Wesleyan University | College/University | Undergraduate Degree Graduate Degree | |
Presidio Partners
 Presidio Partners Investment ManagersFinance Presidio Partners is a venture capital firm founded in the year 1989 by Thomas R. Baruch. The firm is headquartered in San Francisco, California. | Investment Managers | Director/Board Member Private Equity Investor Director/Board Member | |
| The State University of New York | College/University | Doctorate Degree | |
Ferring Pharmaceuticals, Inc.
 Ferring Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ferring Pharmaceuticals, Inc. develops and markets fertility and endocrinology products. Its products include Bravelle, Repronex, Novarel, Acthrel and Desmopressin Acetate. The company's products are used in treatment of osteoarthritis, prostate cancer, and other infertility related diseases. Ferring Pharmaceuticals was founded in 1951 and is headquartered in Parsippany, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Tech/Sci/R&D Officer | |
Merck Serono SA
 Merck Serono SA Medical SpecialtiesHealth Technology Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland. | Medical Specialties | Chief Tech/Sci/R&D Officer | |
Physic Ventures LLC
 Physic Ventures LLC Investment ManagersFinance Physic Ventures LLC (Physic Ventures) is a venture capital firm founded in 2006 by Dion Madsen and Will B. Rosenzweig. The firm is headquartered in San Francisco, California. | Investment Managers | Corporate Officer/Principal | |
Women's Forum, Inc.
 Women's Forum, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Leadership Foundations, Women's Forum, Inc. is a non-profit community for women leaders of diverse achievement. The company is based in New York, NY. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Novartis Institute for Functional Genomics, Inc.
 Novartis Institute for Functional Genomics, Inc. Miscellaneous Commercial ServicesCommercial Services Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Corporate Officer/Principal Chairman | |
Kuur Therapeutics Ltd.
 Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Chairman | |
| THERACLION | Medical Specialties | Director/Board Member | |
| SAGIMET BIOSCIENCES INC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member | |
| The University of Cincinnati College of Medicine | College/University | Doctorate Degree | |
| St Bartholomew's Hospital Medical College | College/University | Doctorate Degree | |
Transcelerate Biopharma, Inc.
 Transcelerate Biopharma, Inc. BiotechnologyHealth Technology Transcelerate Biopharma, Inc. is a non-profit consortium that collaborates with pharmaceutical and biotechnology companies to improve the delivery of new medicines. The non-profit company is based in King of Prussia, PA. The organization's mission is to identify, prioritize, design, and facilitate implementation of solutions to drive the efficient, effective, and high-quality delivery of new medicines. Transcelerate has 20 member companies and 30+ initiatives focused on improving the patient and site experience, enhancing sponsor efficiencies and drug safety, and harmonizing processes and sharing information. The company was founded by Garry Arthur Neil, and Janice Chang has been the CEO of the company since 2014. | Biotechnology | Director/Board Member Chairman | |
| DIMENSION THERAPEUTICS INC | Biotechnology | Chief Executive Officer |
Statistieken
Internationaal
| Verenigde Staten | 36 |
| Canada | 7 |
| Verenigd Koninkrijk | 5 |
| Zwitserland | 2 |
| Nederland | 2 |
Sectoraal
| Health Technology | 24 |
| Consumer Services | 13 |
| Commercial Services | 6 |
| Technology Services | 4 |
| Health Services | 4 |
Operationeel
| Director/Board Member | 158 |
| Corporate Officer/Principal | 82 |
| Independent Dir/Board Member | 42 |
| Founder | 26 |
| Chief Tech/Sci/R&D Officer | 26 |
Sterkste connecties
| Insiders | |
|---|---|
| Annalisa Jenkins | 51 |
| David Collier | 24 |
| Jeremy S. Caldwell | 22 |
| Peter G. Schultz | 21 |
| Jan Lundberg | 21 |
| Gordon Ringold | 20 |
| Jean-Paul Castaigne | 18 |
| Christopher Henney | 18 |
| William Bertrand | 16 |
| Paul Korner | 14 |
| Ela Borenstein | 13 |
| Jamie Stiff | 13 |
| Richard Rodgers | 13 |
| Bogdan Dziurzynski | 13 |
| Robert Bazemore | 11 |
- Beurs
- Insiders
- Mark E. Kaufmann
- Bedrijfsconnecties
